Arvinas and Pfizer to Co-develop and Commercialize Breast Cancer Therapy
Arvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read moreArvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read moreQIAGEN officially confirmed a global cooperation agreement with Sysmex Corporation for the development and commercialization of cancer companion diagnostics, leveraging
Read morePhilip Morris International Inc (PMI) has confirmed entering into a deal for DKK 5.1 billion (approximately USD 820 million) to
Read moreKite, a Gilead Company, and Shoreline Biosciences have announced a $2.3 Billion strategic partnership to develop novel cell therapies across
Read moreDanish multinational pharmaceutical company Novo Nordisk and Japanese cardiac regenerative medicine specialist Heartseed have confirmed an exclusive global partnership and license
Read moreCharles River Laboratories International confirmed signing a definitive contract to acquire Vigene Biosciences, a leading gene therapy contract development and manufacturing
Read moreEli Lilly and Company and MiNA Therapeutics, a pioneer in RNA activation therapeutics, have announced a worldwide research partnership to
Read moreLow-income countries can benefit from the latest Moderna – Gavi agreement, which is set up to distribute up to 500
Read morePfizer announced on Wednesday, the acquisition of Amplyx Pharmaceuticals, Inc., a privately-owned company focused on the engineering of treatments for
Read moreThermo Fisher Scientific expands clinical research service offering to pharma and biotech customers with a CRO giant PPD acquisition. Thermo
Read more